白云山:分公司盐酸曲美他嗪缓释片获药品注册证,适用于治疗稳定型心绞痛

财经网
22 Jul

近日,白云山发布关于分公司收到药品注册证书的公告。披露白云山制药总厂收到国家药品监督管理局核准签发关于盐酸曲美他嗪缓释片(35mg)的《药品注册证书》。曲美他嗪临床适用于一线抗心绞痛疗法控制或无法耐受的稳定型心绞痛。盐酸曲美他嗪原研厂家是法国施维雅药厂,盐酸曲美他嗪缓释片于 2010 年 6 月 4 日在中国首次获批上市。2024 年 1 月 4 日,白云山制药总厂向国家药品监督管理局递交药品上市...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10